MF-300

N/A

Report date: 2025/07/22 16:29:55
NME

Base Information

Drug NameMF-300
Drug Alias NameMF-300
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of Action15-hydroxyprostaglandin dehydrogenase [NAD(+)] inhibitors
Targets15-hydroxyprostaglandin dehydrogenase [NAD(+)]
Therapy Area/IndicationsFibrosisSarcopeniaMuscular Atrophy, Spinal +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesEpirium Bio Inc
China Registration ClassN/A

Develop Information

Active CompaniesEpirium Bio Inc
Inactive CompaniesN/A
Active IndicationsFibrosisSarcopeniaMuscular Atrophy, Spinal +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A